Introduction: Subcutaneous (SC) injection is a common route of drug administration; however, injection site pain (ISP) might create a negative patient experience. We evaluated ISP, bioequivalence, and overall safety of the citrate-free (CF) formulation of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A.
Methods: Two phase 1, single-blind studies were conducted in healthy participants. The crossover study A (NCT03848403) evaluated pain intensity on injection as measured by visual analog scale of pain (VAS) scores. Subjects (N = 70) were randomized 1:1:1 at the beginning to three possible treatment sequences and received a 1 mL SC injection of the three formulations sequentially in the abdomen on days 1, 8, and 15, respectively. A mixed-effects repeated measures analysis model was used to analyze VAS score by time post-injection. Study B (NCT04259346) evaluated the bioequivalence of a single 80 mg dose of CF formulation compared to the original commercial formulation. Subjects (N = 245) were randomized 1:1 to either commercial or CF formulation and received a single SC injection into the abdomen, arm, or thigh.
Results: Primary endpoint was achieved in both studies. In study A, least-squares mean (LSM) difference of VAS scores immediately post injection between commercial (n = 61) and CF formulation (n = 63) was - 21.7 (p < 0.0001), indicating a lower degree of pain associated with CF formulation. In study B, bioequivalence of the CF formulation was established as 90% CIs for the ratio of geometric LSM AUC, AUC, and C between treatments were contained within the prespecified limits of 0.8 and 1.25. Except for less ISP in the CF formulation, overall safety profile was comparable.
Conclusion: Ixekizumab CF formulation proved to be bioequivalent, was associated with less ISP, and had no other notable differences in the safety profile compared to the original commercial formulation.
Trail Registration: ClinicalTrials.gov identifier NCT03848403, NCT04259346.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022732 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02126-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis.
Expert Opin Drug Saf
September 2024
Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Article Synopsis
- Biological medications have greatly enhanced treatment outcomes for psoriasis, but they often require subcutaneous administration, leading to injection site reactions (ISRs) that can cause swelling, redness, itchiness, and pain.
- A review highlighted the differences in ISR rates among various biologic drugs, with etanercept and adalimumab having higher rates (37% and 20%, respectively), while newer formulations like citrate-free ixekizumab and certain anti-IL23 drugs showed lower ISR risks.
- To minimize ISR risks, it's essential for healthcare providers to educate patients on proper injection techniques and consider the unique profiles of biologic drugs during treatment decisions.
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF).
Expert Opin Biol Ther
July 2024
Specialty Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Article Synopsis
- - The VOLTAIRE-HCLF study evaluated the bioavailability, pharmacokinetics, immunogenicity, and safety of two formulations of the biosimilar adalimumab-adbm (Cyltezo®) in 200 healthy volunteers aged 18-55, comparing a high-concentration version with a reference version.
- - Results showed that the pharmacokinetic parameters for both formulations were similar, falling within the bioequivalence range, and there were no significant differences in anti-drug antibodies or their titers between the groups.
- - Participants receiving the high-concentration formulation experienced fewer adverse events and local reactions, indicating that both formulations were well tolerated and safe.
Article Synopsis
- Hyrimoz (SDZ-ADL) is a biosimilar to Humira, approved by the FDA and EMA in 2018 and has a new citrate-free formulation approved in 2023.
- Its approval was based on the Totality of Evidence approach, which included comprehensive data on its analytical, functional, pharmacokinetic, and clinical similarities to the reference medicine.
- Multiple studies demonstrated that SDZ-ADL and Humira have no significant differences in safety, efficacy, and immunogenicity, supporting its use in various patient groups.
Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review.
Adv Ther
May 2024
Department of Rheumatology, Advocate Health Medical Group, Franklin, WI, USA.
Article Synopsis
- Adalimumab (ADL), a biologic treatment for chronic inflammatory diseases, is expensive, prompting the emergence of more affordable biosimilars that perform similarly.
- This review highlights how factors like formulation, injection volume, and device design affect patients' experiences with injection-site pain (ISP).
- In the USA, the availability of biosimilars includes designations of interchangeability, impacting how these products can be substituted at pharmacies, with varying degrees of regulation and clinical evaluation in progress.
Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab.
Adv Ther
April 2024
Dermatology San Antonio, San Antonio, TX, USA.
Introduction: A new, citrate-free ixekizumab formulation, which is bioequivalent to the original formulation, was associated with significant reduction in injection site pain. This study evaluates patient satisfaction with the first injection experience of citrate-free ixekizumab in a real-world setting.
Methods: A non-interventional, observational, web-based survey of adults (≥ 18 years) with psoriasis, psoriatic arthritis, or axial spondyloarthritis was conducted between August 2022 and March 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!